Trastuzumab

Trastuzumab is a monoclonal antibody drug (brand name Herceptin) that targets cells overexpressing the HER2 protein. It is most established as a treatment for HER2-positive breast and gastric cancers, and newer formulations such as trastuzumab deruxtecan (Enhertu) are being studied and used in HER2-expressing lung cancers and other solid tumors. It is delivered by intravenous infusion, usually alongside chemotherapy or other targeted agents.

Origin

Developed by Genentech in the 1990s and approved by the FDA in 1998 for HER2-positive metastatic breast cancer, trastuzumab was one of the first targeted monoclonal antibody therapies for a solid tumor. Its generic name follows WHO naming rules: the '-tuzumab' suffix designates a humanized monoclonal antibody, and the 'tras-' stem is unique to this drug.

Significance in Asbestos Context

Trastuzumab is not a standard treatment for mesothelioma, which is the cancer most specifically tied to asbestos exposure. Its relevance for asbestos-exposed patients is limited to those with a separate HER2-positive cancer, most often breast or gastric cancer, or a subset of non-small cell lung cancers with HER2 mutations or overexpression. Because asbestos-related lung cancer treatment depends heavily on tumor biomarker testing, knowing whether HER2 (and other markers like EGFR, ALK, PD-L1) has been tested can change which therapies are available. Treatment records showing the use of trastuzumab or related HER2-targeted drugs may also be relevant to documenting the cost and course of care in a claim.

Example Sentence

"After her lung tumor was found to have a HER2 mutation, her oncologist added trastuzumab deruxtecan to her treatment plan, and the infusion records were later included in the damages documentation for her asbestos claim."

Related Terms

HER2, monoclonal antibody, targeted therapy, non-small cell lung cancer, biomarker testing, immunohistochemistry

Notes

• Ask your oncologist whether your tumor has been tested for HER2 and other actionable biomarkers. This testing determines whether trastuzumab or similar drugs are even an option.
• Trastuzumab can cause heart (cardiac) toxicity; baseline and periodic echocardiograms or MUGA scans are standard, and you should report any new shortness of breath, swelling, or fatigue.
• Keep copies of infusion records, pathology reports showing HER2 status, and billing statements; these document both your treatment course and the financial impact of your illness.
• If you have mesothelioma rather than lung cancer, ask specifically about mesothelioma-directed therapies (such as platinum-pemetrexed chemotherapy and immunotherapy combinations) rather than HER2-targeted drugs.